Instil Bio, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing novel cell therapies and antibody-based treatments for patients with solid tumors and other cancers with significant unmet needs. The company offers a pipeline that includes autologous tumor infiltrating lymphocyte (TIL) therapies, genetically engineered TIL therapies utilizing its proprietary Co-Stimulatory Antigen Receptor (CoStAR) platform such as ITIL-306 targeting tumor-associated antigens in ovarian, uterine, non-small cell lung (NSCLC), and renal cancers, and in-licensed assets comprising AXN-2510 (IMM-2510), a PD-L1xVEGF bispecific antibody, and AXN-27M (IMM-27M), a next-generation anti-CTLA-4 antibody, both for multiple solid tumors including relapsed/refractory squamous NSCLC. Instil Bio leverages its TaaS (T-cell as a Service) platform for scalable manufacturing of autologous and allogeneic T-cell therapies to address logistical challenges in cell therapy delivery. Founded in 2018 and headquartered in Dallas, Texas, the company conducts operations primarily in the United States with global rights (excluding Greater China) for key assets and conducts clinical trials through its subsidiary Axion Bio. Recent developments include an August 2024 licensing agreement with ImmuneOnco Biopharmaceuticals granting Instil exclusive ex-Greater China rights to AXN-2510 and AXN-27M for an upfront payment, near-term milestones up to $50 million, and potential milestones exceeding $2 billion plus royalties; a July 2024 15-year lease with AstraZeneca for its U.S. cell therapy manufacturing facility generating over $7.5 million in annual base rent; FDA clearance of an IND application for AXN-2510 in July 2025; first patient dosing in a Phase 1 monotherapy trial of AXN-2510 by Axion Bio in October 2025; and updated clinical data presentations by ImmuneOnco at the 2025 World Conference on Lung Cancer, with plans for a Phase 1b/2 U.S. trial by year-end 2025. Instil Bio targets oncology markets, particularly solid tumors, and maintains cash reserves of approximately $83 million as of September 30, 2025, funding operations beyond 2026 while exploring further in-licensing opportunities.
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
TIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & Korsinsky
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
Instil Bio shares slide on discontinuation of lead clinical programs
Instil Bio Pulls Plug On Lead Drug Development
Instil Bio shares slide on discontinuation of lead clinical programs
Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Instil Bio Announces ImmuneOnco's Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)